An interventional study of Structured Lifestyle Education and Standard Care (in control arm) in Perimenopause, Postmenopause and Menopause, sponsored by Konya Beyhekim Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 40 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Konya Beyhekim Training and Research Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 393 studies in Sleep Initiation and Maintenance Disorders with a site in Turkey — 98 open to participants now, 111 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Turkey.
Among the 393 studies in Sleep Initiation and Maintenance Disorders with a site in Turkey, this one is the 48th largest by planned enrollment of the 311 interventional ones that give a count, is one of 68 that started in 2026, is one of 309 with no phase, reaches primary completion later than 102 of the 110 other live ones, and was the 378th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →98 of the 393 studies in Sleep Initiation and Maintenance Disorders with a site in Turkey are open now. Recruiting first, the newest first:
Mersin University · Sites in Turkey
Ages 18+
Dokuz Eylul University · Sites in Turkey
Ages 18+
Gazi University · Sites in Turkey
Ages 50–60 · Women only
Medipol University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Sites in Turkey
Ages 18–60
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 40 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
393 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 68 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 60 across the 311 interventional studies, 120 across the 82 observational. Of the 263 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 393 have an industry lead sponsor. The 10 most frequent:
Konya Beyhekim Training and Research Hospital is the lead sponsor of 33 studies on the registry; 15 are open to participants now.
Konya Beyhekim Training and Research Hospital has 1 study filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
35 of the studies in Sleep Initiation and Maintenance Disorders with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07503080Filiz KeskinVirtual Reality (VR) Based Relaxation for Nausea and Comfort in Pregnancy | 2026-11 |
| NCT07933263Inonu UniversityThe Effect of Post-Caesarean Section Transcutaneous Electrical Nerve Stimulation(Tens) Treatment on the Severity of Pain, Mobility and Insomnia: A Randomised Controlled Trial | 2026-12 |
| NCT07499245Kafkas UniversityThe Effect of Virtual Reality in Older Adults | 2026-12 |
| NCT07832721Volkan GokmenSleep, Mindfulness, and Shift-Level Safety Performance in Perianesthesia Nurses | 2026-12 |
| NCT07718399Halic UniversitySpirulina Supplementation in Postmenopausal Women | 2026-12 |
Add all 35 to your calendar (.ics) → With an account.
Among the 393 studies in Sleep Initiation and Maintenance Disorders with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Menopause is a biological process characterized by the permanent cessation of menstruation, often accompanied by vasomotor symptoms, sleep disturbances, anxiety, and impaired quality of life. In primary healthcare settings, structured lifestyle interventions offer low-cost, safe, and sustainable non-pharmacological management strategies.
The objective of this prospective, randomized controlled trial is to evaluate whether a structured lifestyle educational intervention leads to significant improvements in menopausal symptom severity, sleep quality, and anxiety levels compared with a control group receiving routine clinical care among perimenopausal and postmenopausal women aged 40 to 55 years. Primary and secondary outcomes are evaluated using the Menopause Rating Scale (MRS), Pittsburgh Sleep Quality Index (PSQI), and Generalized Anxiety Disorder-7 (GAD-7) at baseline and at 24 weeks.
Background and Objective:
In perimenopausal and postmenopausal women aged 40-55 presenting to primary care, this study evaluates the impact of a structured lifestyle modification program on menopausal symptoms, sleep quality, and anxiety compared with a control group.
Methods and Design:
This prospective, parallel-group, randomized controlled trial is conducted at Selcuklu Ardicli Educational Family Health Center (Units 218, 225, 239, 240) affiliated with Konya Beyhekim Training and Research Hospital.
Eligible women aged 40-55 years with baseline MRS scores between 9 and 31 will be randomized in a 1:1 allocation ratio using a computer-generated block randomization list (block size of 4) via sequentially numbered, opaque, sealed envelopes:
Intervention Group: Receives face-to-face structured educational counseling covering physical activity recommendations, dietary guidance, sleep hygiene, and stress reduction principles at baseline. Re-evaluation is performed face-to-face at 24 weeks.
Control Group: Receives standard clinical care without structured lifestyle education. At the end of the 24-week follow-up and completion of final questionnaires, the same lifestyle education is provided to ensure equal contribution to both groups.
Outcome Assessments:
Questionnaires administered at baseline and Week 24:
Menopause Rating Scale (MRS) for somatic, psychological, and urogenital symptoms.
Pittsburgh Sleep Quality Index (PSQI) for subjective sleep quality over the previous month.
Generalized Anxiety Disorder-7 (GAD-7) for anxiety symptoms over the past two weeks.
In addition, national electronic health records (e-Nabız) will be reviewed at Month 6 for new antidepressant initiation, systemic hormone replacement therapy initiation, prescription counts of non-steroidal anti-inflammatory drugs (NSAIDs), and emergency department visits.
Sample Size Calculation:
Calculated using G*Power 3.1.9.4 with repeated measures ANOVA (within-between interaction; effect size f=0.20, alpha=0.05, power=0.95, 2 groups, 2 measurements, correlation=0.50), yielding a minimum of 84 participants. Accounting for a 10% dropout rate, a total of 100 participants (50 intervention group, 50 control group) will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients aged 40 to 55 years presenting to the Educational Family Health Center
Categorized into one of the defined reproductive stages: late perimenopause, early (0-5 years), or late postmenopause (>5 years)
Reporting complaints in at least one key menopausal domain: hot flashes/night sweats, sleep problems, or mood changes (anxiety, irritability, depressive mood)
Baseline Menopause Rating Scale (MRS) total score between 9 and 31 (inclusive)
Literate and capable of comprehending and completing study questionnaires
Accessible for the 24-week follow-up evaluation
History of compensated chronic disease (e.g., controlled diabetes mellitus, hypertension, atherosclerotic cardiovascular disease, hyperlipidemia)
Provision of written
Exclusion Criteria:
Age younger than 40 or older than 55 years
History of hysterectomy or bilateral oophorectomy
Severe cognitive impairment or inability to complete questionnaires
Inability or refusal to provide written
Previously diagnosed severe psychiatric illness (e.g., psychotic disorders, bipolar disorder)
Baseline Menopause Rating Scale (MRS) total score \<9 or ≥32
History of decompensated chronic disease (e.g., uncontrolled hypertension, unstable cardiovascular disease, decompensated diabetes mellitus)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive structured education on healthy lifestyle modifications during the menopausal transition, focusing on regular physical activity, dietary guidance, sleep hygiene, and stress reduction principles at baseline. Re-evaluation is performed face-to-face at 24 weeks.
Behavioral: Structured Lifestyle Education
Participants receive standard clinical care without structured lifestyle education during the 24-week study period. Follow-up questionnaires are completed at 24 weeks, after which the healthy living educational information is provided.
Other: Standard Care (in control arm)
Face-to-face structured educational counseling covering regular physical activity recommendations, dietary guidance, sleep hygiene principles, and stress management strategies tailored for perimenopausal and postmenopausal women.
Participants continue with standard routine care and health follow-up without the structured menopause lifestyle education during the first 6 months.
Change from Baseline in Menopause Rating Scale (MRS) Total Score at 24 Weeks
Assessed using the Menopause Rating Scale (MRS), which evaluates somatic, psychological, and urogenital symptoms across 11 items. Each item is scored on a 5-point Likert scale (0=none to 4=very severe), yielding a total score ranging from 0 to 44. Higher scores reflect greater symptom severity. Change is defined as the score at 24 weeks minus the baseline score.
Time frame: Baseline and 24 weeks
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at 24 Weeks
Subjective sleep quality over the previous month assessed using the Pittsburgh Sleep Quality Index (PSQI). The global score ranges from 0 to 21, where scores greater than 5 indicate poor sleep quality. Higher scores reflect worse sleep quality. Change is calculated as the score at 24 weeks minus the baseline score.
Time frame: Baseline and 24 weeks
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Score at 24 Weeks
Anxiety symptoms over the previous two weeks assessed using the Generalized Anxiety Disorder-7 (GAD-7) scale. The total score ranges from 0 to 21, categorized as minimal (0-4), mild (5-9), moderate (10-14), and severe (15-21) anxiety. Higher scores indicate greater anxiety symptom severity. Change is defined as the score at 24 weeks minus the baseline score.
Time frame: Baseline and 24 weeks
Rate of New Medication Initiation (Antidepressants or HRT) at 24 Weeks
Percentage of participants who were prescribed a new antidepressant or systemic hormone replacement therapy (HRT) during the 24-week follow-up period, assessed via electronic health records (e-Nabiz system).
Time frame: From baseline up to 24 weeks
Number of Emergency Department Visits at 24 Weeks
Total number of all-cause and symptom-related emergency department admissions per participant during the 24-week study period, extracted from electronic health records (e-Nabiz system).
Time frame: From baseline up to 24 weeks
Total Count of NSAID Prescriptions at 24 Weeks
Total number of non-steroidal anti-inflammatory drug (NSAID) prescriptions filled per participant over the 24-week follow-up period, assessed via electronic health records (e-Nabiz system)
Time frame: From baseline up to 24 weeks
Plan to share: No — Individual participant data collected during the study will not be shared publicly to protect participant privacy and confidentiality.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for May 2027, 7 months after the start.
Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 7 months is below that.
Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
Konya Beyhekim Training and Research Hospital